 |
N-Acetyl
Carnosine eyedrops
Second interview with Mark
 Babizhayev,
Ph.D.
At the 1st Paris Anti-Aging Conference, February,
2003, Dr. Babizhayev talked about the Russian breakthrough of
N-acetyl carnosine for the treatment of senile cataract. IAS took the
opportunity to interview Dr. Babizhayev further, about the precise role
of N-acetyl carnosine and a number of important factors were raised in
the discussion.
Phil: “Dr. Babizhayev, thank you very much
for joining me here today, to discuss your important breakthrough of an
eye-drop to treat, and possibly to prevent senile cataract. I know by
the response that the readers of the IAS Anti-Aging Bulletin, enjoyed
our previous discussion.”
Dr. Babizhayev: “It’s a pleasure to be in
Paris with you Phil.”
Phil: “As you know, we have already covered
a lot in our previous article and interview, about the development of
N-acetyl carnosine and its role in combating the common aging-disease of
senile cataract. We were made very aware in those, that there are
significant differences between L-carnosine and n-acetylcarnosine, and
we warned everyone then that they shouldn’t use L-carnosine for eye-use.
But tell us, are there any differences in N-acetyl carnosine itself?”
Dr. Babizhayev: We have developed a very
precise product of N-acetylcarnosine, both from the point of view of
purification, and its content of transition metal ions traces. This is
because, rather uniquely, only certain types and levels of impurities
enable the maintenance of the peculiar antioxidant activities of the
released molecule, including those scavenging the hydroxyl radical,
singlet oxygen, lipid peroxidase-like and ferroxidase-like activities.
This very particular active product is responsible for the anti-cataract
efficacy, and for the protection of the lens proteins from the singlet
oxygen-induced oxidation of the lens protein, specifically the aminoacid
tryptophan residues, which have been measured using chemiluminescenece
technique and L-Gly-Tryptophan peptide. Some details of this were
published in one of our papers. (reference 1 below).
Phil: “So, when you were experimenting with
your different N-acetylcarnosines, was there a difference in their
efficacy, or side effects?
Dr. Babizhayev: “Oh yes, sure! With either
too much or too little metals, side-effects were caused, or we saw less
efficacy. The manifested lipid hydroperoxides scavenging activities of
the released carnosine, and the ferroxidase activities of the final
released product in the eye are all very important.”
Phil: “Thus, I imagine, you must have
decided upon a specific N-acetyl carnosine with a narrow range of purity,
that was, in terms of its impurities, not-too-much, not-too-little. Is
that form commonly available?
Dr. Babizhayev: “No, that form is not
commonly available, and the information is kept proprietary. The
specific N-acetyl carnosine in question, is manufactured by our Japanese
partner under a cGMP specific know-how process. Therefore, this material
is currently only available from one source, which is Innovative
Vision Products, the patent holders.”
Phil: “So how can people tell if they are
using the correct material in their eye-drop?”
Dr. Babizhayev: “The packaging should
clearly state that the formula is approved and patented by Innovative
Vision Products/ IVP.”
Phil: “Now we understand the importance of
the type of carnosine and its purity for eye-drops. Are there any
problems in the formula? By which I mean, what happens if you start to
change the formula by adding additional ingredients, etc.?”
Dr. Babizhayev: “Innovative Vision
Products, Inc. has conducted serious pharmacokinetic studies utilizing
precise chromatographic techniques of analysis, and using the final
formulated patented Can-C product and other various possible
formulations. The ratio of carnosine/NAC concentrations upon the topical
application of Can-C to the eye, is equal to 9 in the aqueous humor.
This means that virtually all N-acetyl carnosine is converted to the more
powerful antioxidant L-carnosine in the aqueous humor. This can then
enter the lens tissue and epithelial cells, and act as the anti-cataract
remedy.
N-acetyl carnosine is a delicate molecule. The
biotransformation of N-acetyl carnosine into L-carnosine in unsolicited
external topical formulations, can be promptly inhibited. Active
L-carnosine can not be detected in the aqueous humor after the topical
installation of hydrophobic vitamin-loaded remedies after 15 minutes, at
any significant doses. It is not apparent that when chemicals are mixed
together, chemicals which, by themselves may have efficacy, that the sum
is greater than the single parts. These chemicals interact with one
another, and in the eye, these additional interactions could cause side
effects or lose the efficacy of the original product.”
Phil: “As I understand it, now we know that
the amount of transformation of N-acetyl carnosine into L-carnosine, and
the length of life/ activity of that L-carnosine in the aqueous humor
are all essential elements in the efficacy of N-acetyl carnosine eye-drops. I therefore suspect that you must be concerned about copy-cat
products that claim your research, but actually contain inferior
N-acetyl carnosine and formulas that have little value?”
Dr. Babizhayev: “Yes, I fear that such
inferior products will mar my entire research and maybe people will
think that all N-acetyl carnosine is the same, and that eventually it
will block even the correct product and formula from coming to market.
However, myself and our shareholders are addressing this issue, and in
those countries where such products are currently being used, our
patents there will be in force later this year and we shall pursue
them.”
Phil: “I guess it’s actually part of that
old adage, when we say, the devil is in the detail.”
Dr. Babizhayev: “Indeed it is Phil.”
Phil: “I appreciate that it is still early
days, but do you feel, or do you have any scientific reasoning, if
N-acetyl carnosine will be useful in other eye-disorders?”
Dr. Babizhayev: “Yes, we believe that
N-acetyl carnosine will have a role for glaucoma, especially when
combined with some other substances that we are currently working on. In
particular, we know that N-acetyl carnosine is efficacious for its
anti-glare effect and improvement for color vision. So, for example, we
envisage that this could lead to safer driving, especially night
driving.
Another interesting, recent development is the
fact that we have shown N-acetyl carnosine to prevent and reverse the
acidosis in the corneal stroma due to the actions of accumulated lactic
acid. This means that individuals can wear contact lenses, particularly
soft contact lenses, which are not gas permeable, for longer and with
more comfort.”
Phil: “Have you enjoyed yourself here in
Paris? I mean, professionally of course! What kind of response are you
getting to your trials that show n-acetyl carnosine to be highly
efficacious in the prevention and treatment of senile cataract?”
Dr. Babizhayev: “Yes, the response wherever
I go is very favorable and I think that eventually the word about this
breakthrough is going to spread worldwide. We are close to some
arrangements that would probably mean the general media would know and
report about this, when that happens I expect much will change quickly.”
Phil: “I’m sure there will continue to be
some resistance to this breakthrough, after-all, it always takes some
time to accept new ideas, and especially for the mainstream media to
start reporting on it. But then, that’s why people read the IAS
Anti-Aging Bulletin, to be ahead of the crowd, and keep up-to-date on
the cutting-edge.”
Dr. Babizhayev: “Yes, I believe it is a
most worthy enterprise.”
Phil: “Thank you for your time with us here
today and enjoy the rest of your stay in Paris.
Dr. Babizhayev: “Thank you, I will.”
1. 1st
interview with Dr.
Babizhayev click
2. additional
eyedrop article
click
References:
- Babizhayev MA, Lozovskaya EL,
Makareyeva EN, Lulkin YA, Sapezhinskii II,
“Photoprotector and antioxidant properties of histamine containing
peptidomimetics in the photooxidation of glycyltryptophan.”
Biochemistry (Moscow), 1998 May;63(5):523-8.
ALL INFORMATION IS EDUCATIONAL AND
PROVIDED UNDER IAS TERMS AND CONDITIONS AND SHOULD NOT REPLACE THE
ADVICE OF YOUR PHYSICIAN.
The above article is
copyrighted and may not be copied without the written permission of
International Antiaging Systems, Les Autelets Suite A, Sark
GY9 0SF, Channel Islands, UK
Can CTM
ingredients
Active ingredients Glycerin (lubricant) 1.0% Carboxymethylcellulose sodium
(lubricant) 0.3%
Inactive Ingredients Sterile water (ophthalmic grade isotonic solution, pH 6.3 to
6.5); antioxidants N-Acetyl-Carnosine (NAC) 1.0%, buffered with borates and
potassium bicarbonate and as a preservative, purified benzyl alcohol.
Articles
1.
Centrophenoxine
- the anti-aging brain booster
2.
Piracetam
- the original nootropic
3.
Nootropics
- piracetam, aniracetam, pramiracetam, and oxiracetam
4.
Attention Deficit
Disorder
5. Vinpocetine
- a cerebral enhancer
6.
Deprenyl - the antiaging way
7.
Pyritinol
- the immune-enhancing Nootropic
8.
Idebenone
- the ultimate anti-aging drug?
9.
Nootropics
- piracetam, aniracetam, pramiracetam, and oxiracetam
10.
NADH - the
supervitamin body and mind energizer
11.
Depression
- new drugs, reboxetine, tianeptine, moclobemide
12.
Weight
Loss
13.
SAMe - the nutrient for mood, liver, heart, joint and brain protection
14.
Immune
system
15.
Growth
Hormone - the
real "fountain of youth!"
16.
Quercetin &
Resveratrol- Anti Heart & Anti Cancer Duo
17.
Tired
of being Tired?
|
